Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Servier Laboratories Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to ensure the safety, quality, and efficacy of therapeutic goods available in Australia. This legislation was introduced to address the need for comprehensive regulation of therapeutic goods, including medicines, medical devices, and blood products. The Therapeutic Goods Act 1989 is administered by the Therapeutic Goods Administration, an agency of the Department of Health within the Australian Government. The policy objective of this Act is to protect public health by ensuring that therapeutic goods available in Australia meet necessary standards for safety, quality, and efficacy. The Act provides a framework for the regulation of therapeutic goods through licensing, approval processes, and post-market surveillance. One of the mechanisms through which this is achieved is the ability to provide consents for deviations from certain regulatory requirements, as demonstrated in the case of the perindopril erbumine products mentioned.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration, applies to a wide range of therapeutic goods including medicines, medical devices, blood and blood components, and poisons. This Act is applicable to entities such as manufacturers, importers, suppliers, and sponsors of these goods, ensuring they meet the necessary safety, quality, and efficacy standards. The Act operates on a national level across Australia, providing a cohesive regulatory framework for therapeutic goods. However, specific labelling requirements, such as those addressed in the Therapeutic Goods Order No. 69, are subject to certain exclusions or consents that may allow for deviations under particular circumstances. In the case of the consent provided to Servier Laboratories Australia Pty Ltd, it allows for the importation and supply of certain perindopril erbumine products that do not conform to specific labelling standards, provided that specific conditions, such as the inclusion of a 'Dear Pharmacist' letter, are met. This consent is effective for the specified batches until they are exhausted, illustrating how the Act can be applied flexibly through subordinate instruments to address specific issues while maintaining overall regulatory integrity.

Key Provisions

The Therapeutic Goods Act 1989 (sections 14 and 14A) provides the authority for the Therapeutic Goods Administration to consent to certain actions that would otherwise be non-compliant with the legislative requirements. In this case, Servier Laboratories Australia Pty Ltd applied for and was granted consent to import and supply specific batches of perindopril erbumine products, which do not conform to certain labelling requirements outlined in Therapeutic Goods Order No. 69 (paragraph 3(2)(h) and (i)). These products include various brands and dosages of perindopril erbumine with specific batch numbers, and the non-compliance pertains to the lack of appropriate prefixes for batch and expiry details on the blister packs. Under the Act, the consent granted to Servier Laboratories Australia Pty Ltd includes specific conditions that must be met to ensure compliance with the therapeutic goods regulatory framework. The primary condition is the provision of a 'Dear Pharmacist' letter with each batch of the affected products. This letter must contain text identical to that provided to the Therapeutic Goods Administration and must remind pharmacists to inform patients to keep the blister packs with the correctly labelled carton. This measure aims to ensure that despite the non-conformance of the blister packs, patients are still provided with accurate information about the product. The Therapeutic Goods Act 1989 imposes several obligations on entities such as Servier Laboratories Australia Pty Ltd, including adherence to labelling requirements and ensuring that any deviations from these requirements are appropriately managed and communicated. In this instance, the company must ensure that each affected batch is accompanied by the required 'Dear Pharmacist' letter. Failure to comply with these conditions could result in enforcement actions by the Therapeutic Goods Administration. For breaches of the Therapeutic Goods Act 1989, the Act provides for both civil and criminal penalties. Civil penalties may include fines up to a significant amount, depending on the severity and frequency of the breach. Criminal penalties can also apply, with potential fines and imprisonment for individuals or corporations found guilty of serious or repeated breaches. The specific penalties are outlined in the Act and can vary based on the nature and impact of the non-compliance.